FLUNISOLIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLUNISOLIDE (FLUNISOLIDE).
Corticosteroid with anti-inflammatory action; inhibits release of inflammatory mediators (e.g., histamine, leukotrienes), reduces eosinophil migration, and stabilizes mast cells. Suppresses cytokine production and adhesion molecule expression.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by other CYP450 enzymes. Undergoes first-pass metabolism. |
| Excretion | Renal (50%) as metabolites, fecal (40%) as metabolites via bile, <5% unchanged in urine. |
| Half-life | Terminal elimination half-life is 1.8 hours (range 1.3–2.5 h) after intravenous administration; clinically, endogenous suppression persists up to 24 h post-inhalation. |
| Protein binding | Approximately 40% bound to plasma proteins (albumin); metabolites may have lower binding. |
| Volume of Distribution | Approximately 1.8 L/kg (range 1.3–2.5 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Intranasal: <50% (due to mucociliary clearance and minimal absorption; systemic bioavailability ~21%). Oral inhalation: Not indicated; swallowed portion has ~20% oral bioavailability due to first-pass metabolism. |
| Onset of Action | Intranasal: 2–3 hours (relief of nasal symptoms). Oral inhalation: not applicable (primarily intranasal use). |
| Duration of Action | Intranasal: 12–24 hours (once-daily dosing for maintenance; may require twice-daily dosing initially). |
50 mcg per nostril twice daily (total daily dose 200 mcg), via nasal spray.
| Dosage form | SPRAY, METERED |
| Renal impairment | No adjustment required; flunisolide is primarily hepatically cleared. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Children 6-14 years: 50 mcg per nostril twice daily (total daily dose 200 mcg). Children <6 years: not recommended. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLUNISOLIDE (FLUNISOLIDE).
| Breastfeeding | No studies exist on flunisolide in breast milk. Systemic absorption is low; M/P ratio unknown but expected to be low due to minimal bioavailability. Inhaled corticosteroids are generally considered compatible with breastfeeding at therapeutic doses. Caution with high doses. Monitor infant for corticosteroid side effects (e.g., growth suppression). |
| Teratogenic Risk | Flunisolide is an inhaled corticosteroid. Data on use in pregnant women are limited but suggest low risk. Systemic absorption is minimal, and no increased risk of major congenital malformations has been reported. However, animal studies at high doses have shown fetal harm. First trimester: No specific pattern; background risk. Second/third trimester: Potential for fetal growth restriction with prolonged high-dose systemic exposure, but minimal with inhaled route. Avoid excessive doses. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to flunisolide or any component","Untreated localized nasal infections (e.g., Candida)"]
| Precautions | ["May cause growth retardation in children","Risk of adrenal suppression with prolonged use","Increased risk of nasal septal perforation and Candida infections","May mask signs of infection","Avoid use in patients with active tuberculosis or untreated fungal/bacterial/viral infections"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required, but assess asthma control regularly. Monitor fetal growth if high-dose or prolonged use. In cases of poor asthma control, consider pulmonary function tests. |
| Fertility Effects | No known effect on fertility in humans. In animal studies, no impairment was observed. |